BLU - Dosing underway in Phase 2 BLUEPRINT Trial of BLU-5937 in Atopic Dermatitis

BELLUS Health (BLU) has dosed the first patient in the Phase 2 BLUEPRINT trial of BLU-5937, the company’s highly selective P2X3 antagonist, in patients with chronic pruritus associated with atopic dermatitis.The 128-subject trial will be randomized into one of two treatment arms (1:1) and will receive either 200 mg BID of BLU-5937 or placebo for a four-week treatment period.The primary efficacy endpoint will be the change from baseline in weekly mean Worst Itch-Numeric Rating Scale (WI-NRS) score at week four.The study will be performed at approximately 29 study centers located in Canada and the United States. The company looks forward to report topline data from this trial in 4Q21.Shares up 0.6% premarket.

For further details see:

Dosing underway in Phase 2 BLUEPRINT Trial of BLU-5937 in Atopic Dermatitis